08 October 2019
By Dr Wendy Winnall - PCFA Research Team
PARP inhibitors are new drugs that are being developed for prostate cancer. They won't work for all men but are designed to treat men with defects in DNA repair genes. Four different PARP inhibitors look promising in early clinical trials. Researchers hope that a PARP inhibitor will be the first precision medicine for prostate cancer. This week’s blog summarises the latest clinical trials testing PARP inhibitors for men with late-stage prostate cancer.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
